Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer

Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer

(2021) Hengrui Liang et al.   Translational Lung Cancer Research

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

(2020) Catherine A Shu et al.   LANCET ONCOLOGY

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

(2020) Mariano Provencio et al.   LANCET ONCOLOGY

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

(2019) Jhanelle E. Gray et al.   Journal of Thoracic Oncology

Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors

(2018) Matthew J. Bott et al.   ANNALS OF THORACIC SURGERY

Initial results of pulmonary resection following neoadjuvant nivolumab in patients with resectable non-small cell lung cancer

(2018) Matthew J. Bott et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

RECIST 1.1—Update and clarification: From the RECIST committee

(2016) Lawrence H. Schwartz et al.   EUROPEAN JOURNAL OF CANCER

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy

(2012) Apar Pataer et al.   Journal of Thoracic Oncology